Breaking News

Tweet TWEET

Science Behind the Numbers, The Business of Health - Research Report on Endo Health Solutions Inc, Actavis Inc, Mylan Inc., Elan

 Science Behind the Numbers, The Business of Health - Research Report on Endo
   Health Solutions Inc, Actavis Inc, Mylan Inc., Elan Corporation, plc and
                                 Amgen, Inc.

PR Newswire

NEW YORK, February 28, 2013

NEW YORK, February 28, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Endo
Health Solutions Inc (NASDAQ: ENDP), Actavis Inc (NYSE: ACT), Mylan Inc.
(NASDAQ: MYL), Elan Corporation, plc (NYSE: ELN) and Amgen, Inc. (NASDAQ:
AMGN). Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the links
below.

Endo Health Solutions Inc Research Report

Endo Health Solutions gained 7.9 percent after the company named Rajiv De
Silva as president and CEO. Rajiv De Silva's experience includes serving as
President of Valeant Pharmaceuticals. His turnaround plan for Valeant resulted
in significant increases in revenue through acquisitions and organic sales
growth. Many believe that under his leadership, Endo is bound for recovery.
According to Roger Kimmel, chairman of Endo, Rajiv is a strong leader with
deep industry experience and has a track record in generating growth and
profitability. A few weeks ago, it was also reported that Endo is exploring
talks with drug makers that are potentially interested in acquiring the
company. Endo has not issued a statement regarding the potential buyout, but
UBS analysts comment that it would not be surprising if global specialist
pharmaceutical companies or financial buyers end up bidding for Endo. Endo's
largest shareholder, Fidelity Investments, is also pushing the drug maker to
consider a sale. Endo is scheduled to report its fourth quarter earnings on
Feb. 28. The Full Research Report on Endo Health Solutions Inc - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/49e0_ENDP]

--

Actavis Inc Research Report

Actavis just came from a strong fourth quarter, with net revenue up 29 percent
to $5.91 billion. Moreover, Actavis announced that the US Food and Drug
Administration (FDA) approved the Abbreviated New Drug Application (ANDA) for
Buprenorphine HCI and Naloxone HCI Dihydrate SL Tablet, the generic equivalent
to Reckitt Benckiser Healthcare's Suboxone. The drug is for the maintenance of
opioid dependence. Many are encouraged by the company's strong pipeline and
believe that it is in a position for sustainable long-term growth, especially
with few major drugs that have patents that are due to expire in the near
future. The Full Research Report on Actavis Inc - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/d9b4_ACT]

--

Mylan Inc. Research Report

Mylan Inc.'s subsidiaries have been actively rolling out new products to
customers. First off, Mylan Pharmaceuticals has launched Fenofibrate capsules
USP, the generic version of Lupin Atlantis' S.A. Antara capsules. These
capsules reduce levels of LDL-C, Total-C, triglycerides, and Apo B and to
increase HDL-C in patients with primary hypercholesterolemia or mixed
dyslipidemia. Mylan (Proprietary) Limited also launched a portfolio of
antiretroviral (ARV) products, which are affordable and high-quality treatment
for HIV/AIDS in South Africa. With 184 ANDAs pending FDA approval representing
$80.7 billion in annual sales, many are believe that Mylan is a good bet for
long-term growth. The company is set to report its fourth quarter results on
Feb 27. On average, analysts expect Mylan to report earnings of 64 cents per
share. The Full Research Report on Mylan Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.investors-alliance.com/r/full_research_report/02c5_MYL]

--

Elan Corporation, plc Research Report

Elan Corporation has confirmed that RP Management LLC (Royalty Pharma) has
proposed to buy Elan Corp for $6.5 billion. The informal offer of $11 per
American depositary receipt is 3.8 percent above Elan's closing price on Feb
22. According to Leerink Swann & Co. analyst Marko Kozul, Royalty Pharma is in
"the best candidate for this transaction." According to Elan, it is
considering the deal alongside other strategic transactions. Its other
transactions include selling its stake in the Tysabri multiple-sclerosis drug
to Biogen Inc. The proceeds of this will be used to reinvest in late-stage
experimental products or some early-stage clinical research projects. Elan's
share rose to $11.14 following the announced proposal and many are eager for
the sale of the company. The Full Research Report on Elan Corporation, plc -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/294e_ELN]

--

Amgen, Inc. Research Report

Shares for Amgen rose after Affymax Inc's national voluntary recall of all
Omontys drugs after reports of serious hypersensitivity reactions. Omontys is
used to treat chronic anemia in patients who have chronic kidney disease and
are undergoing dialysis. It is the primary competitor to Amgen's core anemia
drugs Epogen and Aranesp. According to Oppenheimer analyst Boris Peaker,
Epogen, with sales of $1.9 billion in the US, is most likely to benefit from
the Omontys recall. Furthermore, UBS analyst Matthew Roden stated that the FDA
might become more cautious about the safety of newer anemia drugs and generic
versions of biotech drugs following the omontys recall. The Full Research
Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/767e_AMGN]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826

SOURCE Investors-Alliance
 
Press spacebar to pause and continue. Press esc to stop.